Clopidogrel Tablet
Product Images NDC 50090-6568

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-6568). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

189 (Clopidogrel Fig 3)

A forest plot chart showing subgroup analyses comparing Clopidogrel versus placebo with hazard ratios and 95% confidence intervals. The chart includes subgroups based on Heparin/LMWH use, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. It visually represents the favored treatment outcomes for Clopidogrel or placebo with statistical estimates across different patient subgroups.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal forest plot showing the effect of co-administered proton pump inhibitors (Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole) on the active metabolite area under the curve (AUC) of Clopidogrel. The plot displays mean values with 90% confidence intervals for each PPI compared to Clopidogrel administered alone, with a scale ranging from 0.4 to 1.4 on the x-axis representing change relative to Clopidogrel alone.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A cumulative event rate line graph showing cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare PLACEBO (+ aspirin) and CLOPIDOGREL (+ aspirin), with CLOPIDOGREL demonstrating a lower cumulative event rate. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A Kaplan-Meier survival curve chart showing the percentage of patients dead before first discharge over 28 days since randomization. The chart compares Clopidogrel with placebo, indicating 7% proportional risk reduction in deaths with Clopidogrel (1726 deaths, 7.5%) versus placebo (1845 deaths, 8.1%). The x-axis shows days since randomization, and the y-axis shows percentage dead.*

FDA Label Image

146 (Clopidogrel Figure 05)

A Kaplan-Meier curve chart depicting the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. The chart compares two groups: Placebo with 10.1% events and Clopidogrel with 9.2% events, showing a 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up, comparing aspirin and clopidogrel. The x-axis represents months of follow-up, and the y-axis shows cumulative event rate. Clopidogrel's line is slightly below aspirin's line, with a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot chart showing subgroup analyses comparing Clopidogrel to placebo across various patient groups by age, gender, race, enzyme elevation, diabetes status, previous myocardial infarction, and previous stroke. The horizontal axis represents hazard ratios with 95% confidence intervals, indicating the favorability of Clopidogrel versus placebo in these subgroups.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart showing odds ratios with 99% confidence intervals comparing Clopidogrel and placebo across various subgroups based on gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visualizes favorability toward Clopidogrel or placebo for each subgroup and overall outcomes.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A hazard ratio forest plot comparing the effects of Clopidogrel versus Aspirin on outcomes for different qualifying conditions: Stroke, MI, and PAD, plus an overall summary. The horizontal axis shows the hazard ratio with 95% confidence intervals ranging approximately from 0.6 to 1.3. Points and confidence intervals indicate favorability towards Clopidogrel or Aspirin for each condition and overall effect.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of Clopidogrel, depicting its molecular components including a thiophene ring, a bicyclic ring system with a nitrogen atom, a chlorophenyl group, and an ester functional group, along with a sulfate (H2SO4) component.*

FDA Label Image

Label Image (Lbl500906568)

Clopidogrel 75 mg oral tablet label from A-S Medication Solutions. The label includes the NDC 50090-6568-0 and product number 9521-0. It states each tablet contains 75 mg of Clopidogrel bisulfate equivalent to 75 mg of Clopidogrel base. The bottle contains 90 tablets and directs storage at 60 to 70 degrees Fahrenheit. The label also features a QR code and manufacturer location in Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.